Evaluating a new PET/CT scan for thyroid cancer detection
Evaluation of F-18 Tetrafluoroborate (18F-TFB) PET/CT in Patients With Differentiated Thyroid Cancer
This study is testing a new type of PET/CT scan to see if it can better detect recurring thyroid cancer in patients already diagnosed with the disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 24 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Mayo Clinic Academic / other |
| Locations | 1 site (Rochester, Minnesota) |
| Trial ID | NCT05575440 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the effectiveness of fluorine F 18 tetrafluoroborate (18F-TFB) PET/CT scans in patients diagnosed with differentiated thyroid cancer. The study aims to compare the accuracy of this imaging technique against current standard practices for detecting recurrent and metastatic thyroid cancer. Patients will receive an intravenous dose of 18F-TFB and undergo a PET/CT scan to assess its impact on clinical management and treatment planning.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 or older with biopsy-proven papillary or follicular thyroid cancer who are clinically indicated for a total body iodine scan.
Not a fit: Patients who have had recent contrast-enhanced CT scans or are unable to tolerate a PET scan may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved detection and management of differentiated thyroid cancer, enhancing patient outcomes.
How similar studies have performed: Previous studies have shown promising results with advanced imaging techniques in cancer detection, suggesting potential success for this novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subject has biopsy-proven papillary or follicular thyroid cancer * Subject is clinically indicated for 123I-SPECT/CT total body iodine (TBI) scan * Subject agrees to undergo 18F-TFB PET/CT scan following TBI scan * Karnofsky performance status of \>= 50 (or Eastern Cooperative Oncology Group \[ECOG\]/World Health Organization \[WHO\] equivalent) * Subject is able to be scanned - able to lie still on SPECT/CT and PET/CT scanner table for up to 65 minutes (min) * Age 18 or older * Ability to understand a written informed consent document, and the willingness to sign it * Subject is not pregnant Exclusion Criteria: * Contrast-enhanced CT within 4 last weeks * Amiodarone within last 4 months * Ingested iodine, kelp tablets, Lugols iodine, or potassium iodide (SSKI) within 2 weeks * Unable to lie flat, still or tolerate a PET scan * Applied betadine, iodoform, or quick tanning products to skin within last two weeks * If using medication withdrawal for stimulation, then exclude if thyroid stimulating hormone (TSH) level \< 25 * Taken anti-thyroid medication within 1 week * Subject is breastfeeding * Positive pregnancy test
Where this trial is running
Rochester, Minnesota
- Mayo Clinic in Rochester — Rochester, Minnesota, United States (Recruiting)
Study contacts
- Principal investigator: Stephen M. Broski, M.D. — Mayo Clinic in Rochester
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.